RecruitingNot ApplicableNCT06603324

Analysis of Paediatric Treatments With multiFiltratePRO

Efficacy and Safety of Paediatric CVVHD Treatment With MultiFiltratePRO: A Prospective Multicenter Study

Sponsor

Fresenius Medical Care Deutschland GmbH

Enrollment

43 participants

Start Date

Oct 20, 2025

Study Type

INTERVENTIONAL

Conditions

Renal Failure CVVHD

Summary

This clinical study evaluates the performance of the MultifiltratePro in pediatric mode for Continuous Venovenous Hemodiafiltration (CVVHD) in children. Its primary aim is to assess the efficacy of the MultifiltratePro in paediatric mode, specifically in achieving at least 80% of the prescribed effluent dose within 72 hours. Additionally, the study focuses on the safety of this mode in a paediatric setting, closely monitoring for clinical adverse events, hemodynamic instability, and electrolyte imbalances. Paediatric patients with body weights between 8kg and 40kg will be treated with the MultifiltratePro for a period of up to 10 days, with the treatment duration and approach being tailored to the severity of each patient's condition.

Eligibility

Max Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called CVVHD treatment in paediatric mode with multiFiltratePRO for people with cvvhd and renal failure. The study is currently recruiting participants at 2 locations. People eligible for this study include up to age 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.